Tag: Bureau of Competition

Displaying 21 - 40 of 660 results.

Pages

The Federal Trade Commission filed a complaint in federal district court alleging that Endo Pharmaceuticals Inc. and several other drug companies violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost generic versions of Opana ER and Lidoderm. Following...
For more than 15 years, one of the FTC’s top priorities has been to put an end to anticompetitive reverse-payment settlements between brand-name drug makers and their potential generic rivals. In our view, these settlements are anticompetitive agreements not to compete in which the...
Federal Trade Commission staff submitted a comment, as public testimony, to the Alaska legislature on proposed legislation that would allow licensed Alaska physicians located out-of-state to provide telehealth services in the same manner as in-state physicians. 
Federal Trade Commission staff submitted a comment on the competitive implications of proposed legislation that would license and regulate denturists within Kentucky.  Denturists are trained to make and fit removable partial and full dentures. Currently, Kentuckians who need dentures must obtain...
Federal Trade Commission Chairwoman Edith Ramirez issued the following statement regarding the Supreme Court’s denial of certiorari in McWane Inc. v. FTC. The Court declined to review an April 2015 decision of the Eleventh Circuit upholding a Commission cease and desist order against McWane for...
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that national kidney-dialysis chain U.S. Renal Care, Inc.’s $640 million acquisition of competitor DSI Renal from DSI Renal’s ultimate parent company, Dialysis Parent, LLC, would be...
The Federal Trade Commission filed an amicus brief with the U.S. Court of Appeals for the Third Circuit urging the court to correct four legal errors in a district court’s antitrust analysis of an alleged reverse-payment agreement involving brand-name pharmaceutical company GlaxoSmithKline and...
Ten years ago this month, the FTC and DOJ issued the Commentary on the Horizontal Merger Guidelines.
Testifying on behalf of the Federal Trade Commission before the U.S. Senate Judiciary Subcommittee on Antitrust, Competition Policy and Consumer Rights, Chairwoman Edith Ramirez outlined how effective antitrust enforcement benefits both consumers and businesses by preventing mergers and business...
“Oh, if I could but live another century and see the fruition of all the work for women. There is so much yet to be done.” – Suffragist Susan B. Anthony (1820-1906) The consumer movement, trust-busting, the women’s movement, and the work of the FTC have traveled parallel (and often...
There is a basic but important difference between antitrust cases brought by the government and those brought by private parties: All plaintiffs, including government enforcers like the FTC, must prove an antitrust violation, which requires showing harm to competition. But private...
Drug manufacturer Hikma Pharmaceuticals PLC will sell the rights and assets for two generic drugs, and relinquish its U.S. marketing rights to a third generic drug, in order to settle FTC charges that Hikma’s proposed $2 billion acquisition of Roxane would likely be anticompetitive.
The Federal Trade Commission has approved a modified final order settling charges that Mylan N.V.’s proposed hostile takeover of Perrigo Company plc would harm competition. Because Mylan failed to obtain the required threshold of Perrigo shares to succeed in its unsolicited offer, Mylan has...
The Federal Trade Commission will require generic drug marketer Hikma Pharmaceuticals PLC to divest its rights and interests in five generic injectable pharmaceuticals, as part of a settlement resolving charges that Hikma’s $5 million acquisition of the rights to various drug products and related...
Generic drug manufacturers Lupin Ltd. and Gavis Pharmaceuticals LLC will sell the rights and assets for two generic drugs, one used to treat bacterial infections and the other to treat ulcerative colitis, in order to settle FTC charges that Lupin’s proposed $850 million acquisition of Gavis would...
The Federal Trade Commission filed an amicus brief in the U.S. Court of Appeals for the First Circuit urging the court to correct the district court’s holding that a plaintiff must prove an injury-in-fact in order to establish an antitrust violation.
The Federal Trade Commission has submitted to Congress its Fiscal Year 2017 budget request, which includes the FY 2017 Budget Overview Statement, Performance Plan for FY 2016 and FY 2017, and Performance Report for FY 2015, as required under the Government Performance and Results and Modernization...
As part of the Federal Trade Commission’s systematic review of all current FTC rules and guides, the agency is announcing a modified 10-year regulatory review schedule.
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that energy investor ArcLight Energy Partners Fund VI, L.P.’s acquisition of Gulf Oil Limited Partnership from its parent company, Cumberland Farms, Inc., would likely be anticompetitive.
In testimony presented to a U.S. Senate Judiciary subcommittee, the Federal Trade Commission described its competition enforcement and advocacy work relating to state regulatory boards and licensing requirements for occupations, trades, and professions.

Pages